ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

MapKure launched by BeiGene and SpringWorks

by Lisa M. Jarvis
June 22, 2019 | APPEARED IN VOLUME 97, ISSUE 25

 

Chinese biotech firm BeiGene and the Pfizer spin-off SpringWorks Therapeutics have launched MapKure, a cancer-focused biotech firm. MapKure’s main mission is the development of BGB-3245, a small molecule invented by BeiGene that blocks several kinds of BRAF mutations. Although the US Food and Drug Administration has approved drugs to treat V600 BRAF mutations, people whose tumors feature non-V600 BRAF mutations or RAF fusions do not have good options. MapKure plans to study BGB-3245 in people with tumors featuring the range of RAF mutations alongside those who have developed resistance to drugs for V600 BRAF mutations.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment